MSD has published the results of clinical trials of a 15-valent vaccine against pneumococcus. The data obtained are so convincing that the company is preparing to submit registration applications to regulatory authorities around the world, says FiercePharma.
At the same time was presented the data of the two studies: among persons over the age of 18 living with HIV, and patients older than 50 years who also received injections of the vaccine it protects against the flu. In both studies, candidate vaccine V114 contributed to the development of immune response against all 15 serotypes of pneumococcus.
Development MSD competes with experimental pneumococcal vaccine Pfizer intended for prevention of infection of 20 serotypes of streptococcus pneumoniae. Pfizer presented the results of a clinical phase III studies in March and also preparing for the filing of the registration statement.